Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | IDH1 | O75874 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923595 | 1.00 | ADRB1 (0.50) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL30317791 | 1.00 | ADRB1 (0.50) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL28110010 | 0.86 | SLC6A2 (0.46) | IDH1SLC6A3SLC6A4LMNAKDM4E | |
| SCHEMBL28167366 | 0.80 | SLC6A2 (0.42) | IDH1SLC6A3SLC6A4TSHRLMNA | |
| SCHEMBL28110549 | 0.80 | SLC6A2 (0.42) | IDH1SLC6A3SLC6A4TSHRLMNA | |
| SCHEMBL7354322 | 0.80 | SLC6A4 (0.41) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL28969182 | 0.77 | SLC6A3 (0.43) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL22717060 | 0.77 | SLC6A3 (0.43) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL14452294 | 0.77 | ADRB1 (0.42) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| SCHEMBL755824 | 0.77 | S1PR1 (0.38) | SLC6A3SLC6A4TSHRDRD3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-06-12 | — | — | US | disclosed |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | NOVARTIS AG (CH) | 2025-04-29 | — | — | US | disclosed |
| CN-115867545-A | Antiviral 1,3 dioxoindene compounds | 诺华股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | ADRB1 1850/4885ADRA1A 1463/4885MIF 30/4885 |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | ADRB1 1850/4885ADRA1A 1463/4885MIF 30/4885 |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | IRF3, EIF2AK2, ZC3HAV1 | ADRB1 1850/4885ADRA1A 1463/4885MIF 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.